Brief: Teva And Celltrion Announce The Availability Of Truxima
Nov 7 (Reuters) - Celltrion Inc 068270.KS :
* TEVA AND CELLTRION ANNOUNCE THE AVAILABILITY OF TRUXIMA®
(RITUXIMAB-ABBS) INJECTION, THE FIRST BIOSIMILAR TO RITUXAN®
(RITUXIMAB) IN THE UNITED STATES
* TEVA PHARMACEUTICAL - TRUXIMA IS BEING MADE AVAILABLE
THROUGH
PRIMARY WHOLESALERS AT A WAC OF $845.55 FOR 100MG VIAL AND
$4227.75 FOR 500MG VIAL
Source text for Eikon: ID:nBw78jZ8Sa
Further company coverage: 068270.KS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Celltrion Healthcare Co
See all newsBrief: Celltrion USA says Ventegra Will Place FDA-Approved Biosimilar To Avastin , Vegzelma On Its Commercial Formulary As A Preferred Brand
Brief: Celltrion Healthcare To Acquire 92.7 Billion Won Worth Of Own Shares
Brief: Celltrion Healthcare Q3 Operating Profit 50.5 Billion Won, Down 30.4% From Year Earlier
Brief: Celltrion Usa- Announces Distribution And Incorporation Of Yuflyma (Adalimumab-Aaty) To Carepartners Specialty Pharmacy Cost Savings Programs
Brief: Celltrion Healthcare's Merger With Celltrion Approved In Shareholder Meeting -Yonhap